Atara Biotherapeutics, Inc. (ATRA)

Oncology Corporate Profile

Stock Performance

18.5800
-0.4400

3 Month Stock History Chart

HQ Location

701 Gateway Blvd, Suite 200
South San Francisco, CA 94080

Company Description

Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara's lead programs target myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. In September 2014, Atara Biotherapeutics entered into an exclusive option agreement with MSK, under which it has the right to license (pursuant to a negotiated form of license agreement) the exclusive, worldwide rights to three clinical stage T-cell programs, including EBV-CTL, as well as other T-cell programs that are discovered or developed by MSK pursuant to sponsored research funded by the company.

Website: http://www.atarabio.com

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
WT1-CTLWT1 inhibitorMultiple MyelomaI
ATA129 (+ pembrolizumab)EBV-specific cytotoxic T lymphocytes (CTL)Nasopharyngeal cancer (NPC)IMerck
STM-434Activin A inhibitorOvarian cancerI
WT1-CTLWT1 inhibitorPlasma cell Leukemia (PCL)I
STM-434Activin A inhibitorVarious cancer typesI

View additional information on product candidates here »

Source: http://www.atarabio.com

Recent News Headlines

8/21/2017 06:17 am

8/21/2017 06:17 am

8/8/2017 12:17 pm

8/8/2017 06:17 am

8/7/2017 12:17 pm

8/2/2017 12:17 pm

8/2/2017 06:20 am

7/20/2017 06:17 am

7/19/2017 12:17 pm

6/15/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/24/2017 06:17 am

5/10/2017 12:17 pm

5/10/2017 06:17 am

5/4/2017 12:17 pm

5/4/2017 12:17 pm

Atara Bio Expands Management Team, Appoints Joe Newell as Executive Vice President, Chief Technical Operations Officer

4/3/2017 12:00 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., April 03, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company developing meaningful therapies for patients with severe and life-threatening diseases that have been ...

Atara Bio's Collaborating Investigators to Present Interim Results from Phase 1 Trial of the Autologous Version of ATA188 in Patients with Progressive Multiple Sclerosis (MS)

3/17/2017 04:04 pm

[GlobeNewswire] - SOUTH SAN FRANCISCO, Calif., March 17, 2017-- Atara Biotherapeutics, Inc., a biopharmaceutical company focused on developing meaningful therapies for patients with unmet medical needs in diseases that ...